Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Curr Opin Psychiatry ; 36(2): 134-139, 2023 03 01.
Article in English | MEDLINE | ID: covidwho-2228471

ABSTRACT

PURPOSE OF REVIEW: To provide an overview of recently published work on anxiety, focusing on generalized anxiety disorder (GAD) and its treatment. RECENT FINDINGS: Self-reported anxiety symptoms were highly prevalent during the COVID-19 global pandemic in both the general population and in selected groups. There remains divided opinion about whether internet-based cognitive behavioural therapy (CBT) is noninferior to face-to-face CBT for GAD. A systematic review of drug treatment for GAD showed efficacy for selective serotonin reuptake inhibitors (SNRIs), agomelatine, and quetiapine. There may be a place for repetitive transcranial magnetic stimulation in the treatment of GAD. There was some evidence of efficacy for complementary therapies, including physical exercise, yoga, acupuncture, and Withania somnifera (ashwagandha). However, a systematic review of cannabidiol and tetrahydrocannabinol found insufficient evidence of efficacy in anxiety disorders. SUMMARY: Antidepressants and quetiapine show efficacy in the treatment of GAD. Internet-based psychological interventions have a place in the treatment of GAD when face-to-face treatment is inaccessible. There is increasing evidence for the use of physical exercise in the management of GAD. Some other complementary therapies, including cannabinoids, require further, methodologically sound, research.


Subject(s)
COVID-19 , Cognitive Behavioral Therapy , Humans , Quetiapine Fumarate/therapeutic use , Anxiety Disorders/drug therapy , Antidepressive Agents/therapeutic use
2.
Int Psychogeriatr ; 34(8): 687-688, 2022 08.
Article in English | MEDLINE | ID: covidwho-1972494
SELECTION OF CITATIONS
SEARCH DETAIL